AP616A - Treatment of post-herpetic neuralgia with antiviral guanine derivatives. - Google Patents
Treatment of post-herpetic neuralgia with antiviral guanine derivatives. Download PDFInfo
- Publication number
- AP616A AP616A APAP/P/1994/000684A AP9400684A AP616A AP 616 A AP616 A AP 616A AP 9400684 A AP9400684 A AP 9400684A AP 616 A AP616 A AP 616A
- Authority
- AP
- ARIPO
- Prior art keywords
- famciclovir
- treatment
- patients
- placebo
- pain
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 45
- 206010036376 Postherpetic Neuralgia Diseases 0.000 title description 64
- 230000000840 anti-viral effect Effects 0.000 title description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 20
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 54
- 229960004396 famciclovir Drugs 0.000 claims description 52
- 150000001875 compounds Chemical class 0.000 claims description 30
- 208000010201 Exanthema Diseases 0.000 claims description 23
- 201000005884 exanthem Diseases 0.000 claims description 23
- 206010037844 rash Diseases 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- -1 phosphate ester Chemical class 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 description 49
- 229940068196 placebo Drugs 0.000 description 45
- 239000000902 placebo Substances 0.000 description 45
- 208000002193 Pain Diseases 0.000 description 42
- 230000036407 pain Effects 0.000 description 35
- 229940097919 famciclovir 500 mg Drugs 0.000 description 22
- 230000001154 acute effect Effects 0.000 description 21
- 229940104320 famciclovir 750 mg Drugs 0.000 description 20
- 230000003902 lesion Effects 0.000 description 19
- 230000035876 healing Effects 0.000 description 18
- 229960004150 aciclovir Drugs 0.000 description 13
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 230000002354 daily effect Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 206010039509 Scab Diseases 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 9
- 229960001179 penciclovir Drugs 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 230000009467 reduction Effects 0.000 description 7
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 5
- KGSIOVLUJYQLKR-UHFFFAOYSA-N [[4-(2-amino-6-oxo-3h-purin-9-yl)-2-(hydroxymethyl)butoxy]-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=N2 KGSIOVLUJYQLKR-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 230000007485 viral shedding Effects 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000004404 Intractable Pain Diseases 0.000 description 3
- AYWLSIKEOSXJLA-UHFFFAOYSA-N [2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]ethoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=N2 AYWLSIKEOSXJLA-UHFFFAOYSA-N 0.000 description 3
- 208000005298 acute pain Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 208000030090 Acute Disease Diseases 0.000 description 2
- 206010060933 Adverse event Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000003136 immunomodifying effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000002420 orchard Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- BRPTUOYNOCSFRJ-FYZOBXCZSA-N sodium (2S)-4-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)butan-1-olate Chemical class [Na+].Nc1nc(=O)c2ncn(CC[C@H](CO)C[O-])c2[nH]1 BRPTUOYNOCSFRJ-FYZOBXCZSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical compound O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939320485A GB9320485D0 (en) | 1993-10-05 | 1993-10-05 | Pharmaceuticals |
| GB939321255A GB9321255D0 (en) | 1993-10-14 | 1993-10-14 | Pharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9400684A0 AP9400684A0 (en) | 1994-10-31 |
| AP616A true AP616A (en) | 1997-09-15 |
Family
ID=26303637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1994/000684A AP616A (en) | 1993-10-05 | 1994-10-05 | Treatment of post-herpetic neuralgia with antiviral guanine derivatives. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5866581A (es) |
| EP (1) | EP0804199B1 (es) |
| JP (1) | JP3768527B2 (es) |
| CN (1) | CN1082816C (es) |
| AP (1) | AP616A (es) |
| AT (1) | ATE216885T1 (es) |
| AU (1) | AU7788494A (es) |
| CA (1) | CA2173505C (es) |
| CY (1) | CY2375B1 (es) |
| DE (1) | DE69430545T2 (es) |
| DK (1) | DK0804199T3 (es) |
| ES (1) | ES2176258T3 (es) |
| HU (1) | HU226472B1 (es) |
| IL (1) | IL111138A (es) |
| PT (1) | PT804199E (es) |
| WO (1) | WO1995009632A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9600847D0 (en) | 1996-01-16 | 1996-03-20 | Smithkline Beecham Plc | Pharmaceuticals |
| ATE279188T1 (de) * | 1998-07-09 | 2004-10-15 | Warner Lambert Co | Pharmazeutische zusammensetzungen enthaltend gaba-analogen und ein antivirales mittel zur behandlung von herpes zoster |
| US6419934B1 (en) | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | TNF modulators for treating neurological disorders associated with viral infection |
| US20100136106A1 (en) * | 2005-06-08 | 2010-06-03 | Gary Liversidge | Modified Release Famciclovir Compositions |
| WO2013167743A1 (en) * | 2012-05-11 | 2013-11-14 | Akron Molecules Gmbh | Use of compounds for the treatment of pain |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0141927A2 (en) * | 1983-08-18 | 1985-05-22 | Beecham Group Plc | Antiviral guanine derivatives |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0182024B1 (en) * | 1984-09-20 | 1991-04-03 | Beecham Group Plc | Purine derivatives and their pharmaceutical use |
-
1994
- 1994-10-03 IL IL111138A patent/IL111138A/xx not_active IP Right Cessation
- 1994-10-04 CA CA002173505A patent/CA2173505C/en not_active Expired - Lifetime
- 1994-10-04 CN CN94194138A patent/CN1082816C/zh not_active Expired - Lifetime
- 1994-10-04 PT PT94928459T patent/PT804199E/pt unknown
- 1994-10-04 US US08/624,466 patent/US5866581A/en not_active Expired - Lifetime
- 1994-10-04 EP EP94928459A patent/EP0804199B1/en not_active Expired - Lifetime
- 1994-10-04 DK DK94928459T patent/DK0804199T3/da active
- 1994-10-04 AU AU77884/94A patent/AU7788494A/en not_active Abandoned
- 1994-10-04 JP JP51069095A patent/JP3768527B2/ja not_active Expired - Lifetime
- 1994-10-04 AT AT94928459T patent/ATE216885T1/de active
- 1994-10-04 HU HU9600882A patent/HU226472B1/hu unknown
- 1994-10-04 WO PCT/GB1994/002156 patent/WO1995009632A1/en not_active Ceased
- 1994-10-04 ES ES94928459T patent/ES2176258T3/es not_active Expired - Lifetime
- 1994-10-04 DE DE69430545T patent/DE69430545T2/de not_active Expired - Lifetime
- 1994-10-05 AP APAP/P/1994/000684A patent/AP616A/en active
-
2003
- 2003-08-25 CY CY0300059A patent/CY2375B1/xx unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0141927A2 (en) * | 1983-08-18 | 1985-05-22 | Beecham Group Plc | Antiviral guanine derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0804199B1 (en) | 2002-05-02 |
| HUT74076A (en) | 1996-10-28 |
| HU226472B1 (en) | 2008-12-29 |
| ES2176258T3 (es) | 2002-12-01 |
| WO1995009632A1 (en) | 1995-04-13 |
| JPH10513434A (ja) | 1998-12-22 |
| CN1082816C (zh) | 2002-04-17 |
| ATE216885T1 (de) | 2002-05-15 |
| DE69430545T2 (de) | 2002-11-07 |
| HU9600882D0 (en) | 1996-05-28 |
| EP0804199A1 (en) | 1997-11-05 |
| AU7788494A (en) | 1995-05-01 |
| DE69430545D1 (de) | 2002-06-06 |
| AP9400684A0 (en) | 1994-10-31 |
| HK1004115A1 (en) | 1998-11-20 |
| CA2173505C (en) | 2005-03-29 |
| PT804199E (pt) | 2002-09-30 |
| IL111138A (en) | 1997-04-15 |
| JP3768527B2 (ja) | 2006-04-19 |
| CA2173505A1 (en) | 1995-04-13 |
| IL111138A0 (en) | 1994-12-29 |
| US5866581A (en) | 1999-02-02 |
| CY2375B1 (en) | 2004-06-04 |
| CN1135180A (zh) | 1996-11-06 |
| DK0804199T3 (da) | 2002-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Spruance et al. | Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol | |
| Tyring et al. | Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial | |
| US20240269125A1 (en) | Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent | |
| AP616A (en) | Treatment of post-herpetic neuralgia with antiviral guanine derivatives. | |
| Goodman et al. | Prospective double-blind evaluation of topical adenine arabinoside in male herpes progenitalis | |
| US6124304A (en) | Penciclovir for the treatment of zoster associated pain | |
| HK1004115B (en) | Use of penciclovir for the treatment of post herpetic neuralgia | |
| Whitley et al. | Herpes zoster: focus on treatment in older adults | |
| AU696833B2 (en) | Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 7 infection | |
| AU2010201834B2 (en) | Penciclovir or famciclovir for the treatment of recurrent genital herpes with a one-day application | |
| de Bony et al. | Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid | |
| WO1995011027A1 (en) | Use of peniclorin for the treatment of posttherapeutic neuralgia | |
| KR101876019B1 (ko) | 엔-메탄노카르바티미딘을 이용한 대상포진의 치료방법 | |
| EP0735878A1 (en) | Pharmaceuticals | |
| EP2394651A1 (en) | Penciclovir or Famciclovir for the Treatment of Recurrent Genital Herpes With a One-Day Application | |
| US20170252345A9 (en) | Famciclovir for the Treatment of Recurrent Herpes Labialis Using a One-Day Treatment |